VisualSonics unveils ‘revolutionary’ Vevo LAZR imaging system

By Alexandria Pesic

- Last updated on GMT

VisualSonics, a high-resolution micro imaging systems manufacturer, has launched a new imaging system it claims will revolutionise cancer research.

The Toronto, Canada-based company - a subsidiary of SonoSite - said its Vevo LAZR Photoacoustics Imaging System ‘combines the sensitivity of optical imaging with the resolution and depth penetration of high frequency ultrasound,’ allowing researchers to study cancer in its earliest stages of progression and detect and evaluate tumour growth.

Anil Amlani, VisualSonics’s president and CEO, claimed the Vevo LAZR represented the future of pre-clinical research.

“Building on our high frequency ultrasound technology, which is now considered a gold standard for many in vivo applications,” ​he said, “the Vevo LAZR Photoacoustics system offers unique capability to non-invasively capture real-time high-resolution data that is unavailable and unparalleled to any other in vivo anatomical or molecular imaging technology.”

High-frequency

According to VisualSonics, the Vevo LAZR works by capturing high-resolution images – in both 2D and 3D modes - with high-frequency ultrasound. This function allows researchers to superimpose a photoacoustic signal over the ultrasound image to help assess oxygen saturation and blood levels in tissues and organs.

Furthermore, VisualSonics said the system includes an automated multispectral imaging algorithm, enabling researchers to select multiple imaging wavelengths in order to visualise contrast agents, such as nanoparticles and dyes.

The company said its new system could be used for lymph node imaging, study of haemoglobin and oxygen saturation, and targeted imaging of tumour biomarkers, but added that its usefulness was not confined to the study of cancer: the Vevo LAZR may benefit research into diabetes, neurosciences and reproductive biology.

Strong impact

“We believe that Vevo LAZR will have a strong impact on the discovery of new cancer therapies in the pre-clinical market space,” ​continued Amlani, “we will see a translation of these discoveries into practical applications in humans.”

Kevin Goodwin, president and CEO of Sonosite, said VisualSonics had already received a number of pre-orders for its new system, and that he expected demand to grow.

“We are excited that Sonosite and VisualSonics have joined forces to innovate and deliver new breakthrough imaging technologies and we are pleased with the initial customer demand for the new product.”

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers